
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.
SSE:603168.SS
7.68 (CNY) • At close June 11, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 483.96 | 644.97 | 549.537 | 629.765 | 358.231 | 515.957 | 607.438 | 938.883 | 978.732 | 921.671 | 765.582 | 628.141 | 544.758 | 408.681 | 272.552 | 174.535 | 146.516 |
Cost of Revenue
| 246.127 | 288.117 | 227.893 | 224.665 | 184.222 | 174.139 | 169.36 | 213.525 | 230.339 | 242.965 | 224.795 | 194.246 | 180.847 | 137.544 | 110.332 | 89.189 | 87.052 |
Gross Profit
| 237.833 | 356.853 | 321.644 | 405.099 | 174.009 | 341.818 | 438.078 | 725.358 | 748.393 | 678.706 | 540.787 | 433.895 | 363.91 | 271.137 | 162.22 | 85.347 | 59.464 |
Gross Profit Ratio
| 0.491 | 0.553 | 0.585 | 0.643 | 0.486 | 0.662 | 0.721 | 0.773 | 0.765 | 0.736 | 0.706 | 0.691 | 0.668 | 0.663 | 0.595 | 0.489 | 0.406 |
Reseach & Development Expenses
| 57.577 | 64.449 | 59.615 | 102.214 | 27.801 | 26.989 | 26.562 | 29.235 | 29.024 | 31.211 | 27.981 | 22.344 | 18.335 | 13.567 | 0 | 0 | 0 |
General & Administrative Expenses
| 81.76 | 92.635 | 76.918 | 85.346 | 58.404 | 43.256 | 53.702 | 42.378 | 30.718 | 25.172 | 14.687 | 12.39 | 12.669 | 13.288 | 23.27 | 17.667 | 12.607 |
Selling & Marketing Expenses
| 56.181 | 135.334 | 93.275 | 116.364 | 149.136 | 249.736 | 290.44 | 410.182 | 423.206 | 395.659 | 320.14 | 257.245 | 211.063 | 150.251 | 82.668 | 40.774 | 21.51 |
SG&A
| 137.941 | 226.427 | 170.194 | 201.71 | 207.54 | 292.991 | 344.142 | 452.56 | 453.924 | 420.831 | 334.827 | 269.635 | 223.731 | 163.539 | 105.938 | 58.442 | 34.117 |
Other Expenses
| 154.245 | 43.939 | 44.627 | 53.933 | 31.313 | 13.539 | 18.717 | 8.674 | 91.535 | 2.877 | 9.378 | 7.5 | 8.779 | 9.048 | 0.277 | 0.185 | 0.009 |
Operating Expenses
| 349.763 | 334.815 | 274.436 | 357.857 | 266.654 | 333.519 | 395.891 | 504.832 | 508.289 | 474.019 | 387.6 | 310.065 | 257.992 | 189.714 | 109.255 | 60.353 | 35.425 |
Operating Income
| -111.931 | 22.039 | 56.808 | 54.922 | 28.78 | 46.293 | -130.261 | 178.105 | 234.359 | 205.794 | 147.934 | 118.596 | 99.586 | 77.248 | 50.21 | 21.897 | 20.89 |
Operating Income Ratio
| -0.231 | 0.034 | 0.103 | 0.087 | 0.08 | 0.09 | -0.214 | 0.19 | 0.239 | 0.223 | 0.193 | 0.189 | 0.183 | 0.189 | 0.184 | 0.125 | 0.143 |
Total Other Income Expenses Net
| -3.643 | 11.04 | -1.609 | -6.048 | 22.897 | 28.158 | 18.717 | 8.674 | 86.803 | 2.857 | 4.498 | 2.263 | 3.055 | 4.616 | 0.277 | 0.169 | -0.043 |
Income Before Tax
| -115.574 | 33.078 | 55.198 | 48.874 | -176.506 | 16.782 | -111.545 | 186.779 | 321.128 | 208.651 | 152.433 | 120.859 | 102.641 | 81.864 | 50.487 | 22.066 | 20.847 |
Income Before Tax Ratio
| -0.239 | 0.051 | 0.1 | 0.078 | -0.493 | 0.033 | -0.184 | 0.199 | 0.328 | 0.226 | 0.199 | 0.192 | 0.188 | 0.2 | 0.185 | 0.126 | 0.142 |
Income Tax Expense
| 5.92 | 7.974 | 9.26 | 13.218 | 2.864 | 8.925 | 14.93 | 40.422 | 45.411 | 32.615 | 21.163 | 16.776 | 11.755 | 13.952 | 7.392 | 2.982 | 2.79 |
Net Income
| -123.443 | 25.408 | 44.752 | 35.656 | -179.369 | 7.857 | -126.474 | 146.356 | 275.717 | 176.036 | 131.27 | 104.082 | 90.886 | 67.913 | 43.095 | 19.084 | 18.057 |
Net Income Ratio
| -0.255 | 0.039 | 0.081 | 0.057 | -0.501 | 0.015 | -0.208 | 0.156 | 0.282 | 0.191 | 0.171 | 0.166 | 0.167 | 0.166 | 0.158 | 0.109 | 0.123 |
EPS
| -0.33 | 0.07 | 0.14 | 0.11 | -0.56 | 0.024 | -0.39 | 0.45 | 0.93 | 0.59 | 0.51 | 0.47 | 0.41 | 0.31 | 0.19 | 0.086 | 0.081 |
EPS Diluted
| -0.33 | 0.07 | 0.14 | 0.11 | -0.56 | 0.024 | -0.39 | 0.45 | 0.93 | 0.59 | 0.51 | 0.47 | 0.41 | 0.31 | 0.19 | 0.086 | 0.081 |
EBITDA
| -36.319 | 111.253 | 127.039 | 114.161 | 0.118 | 64.393 | 94.881 | 236.86 | 369.421 | 236.287 | 183.314 | 139.077 | 126.405 | 104.266 | 62.823 | 34.27 | 32.441 |
EBITDA Ratio
| -0.075 | 0.172 | 0.231 | 0.181 | 0 | 0.125 | 0.156 | 0.252 | 0.377 | 0.256 | 0.239 | 0.221 | 0.232 | 0.255 | 0.23 | 0.196 | 0.221 |